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ABSTRACT
Pathologically, Alzheimer’s disease is a result of aggregation of amyloid peptides and protein tau in the brain forming 
neurofibrillary tangles which are highly toxic to neuronal circuits in the brain. Recent evidences report that apart from 
aging, estrogen deficiency is one of the risk factors predisposing to the development of Alzheimer’s disease. Isofla-
vones, also known as phytoestrogens, are metabolized by the body forming compounds that are known to interfere with 
neurotoxic pathways and through their anti-fibrillization effects they play a role in reducing apoptosis of neurons and 
glial cells and promote axonal regeneration.  Experimental studies on transgenic models with Alzheimer’s disease as 
well as various observational and clinical trials suggest that dietary interventions with Isoflavones may have a significant 
role in improving portions of memory, cognition and decreasing the risk of Alzheimer’s disease.  
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INTRODUCTION
Ageing, along with dietary habits are the major risk 
factors that contribute to the development of neurode-
generative diseases. Dementia is one of the types of 
neurodegenerative diseases. As age progresses, it leads 
to the loss of brain function affecting cognitive thinking, 
memory and behavior. Prevalence of dementia is 
predicted to double every 20 years worldwide and 
estimated to reach 115.4 million by 2050 (1). 
Alzheimer’s disease (AD) is a form of Dementia. Patho-
logically, it is the aggregation of amyloid peptides and 
protein tau in the brain. These proteinstake a form of 
neurofibrillary tangles which are highly toxic to neuronal 
pathways in the brain (2). Evidences suggest that, apart 
from aging, deficiency of estrogen is also one of the 
factors involved in causing AD, by exposing neurons to 
toxic insults, including A-beta, as a result of which post-
menopausal women are at a significant risk of develop-
ing AD (3,4). Unfortunately, current drug treatments have 
failed to show positive results in the prevention of neuro-
degenerative diseases (5, 6). Consequently, there is an 
increasing interest in dietary interventions. Various inter-
ventional studies have been conducted globally demon-
strating the protective role of antioxidants against AD. 
These antioxidants include Vitamins C, E, Beta Carotene 
and Flavonoids (7-10). Flavonoids belong to a group of 
polyphenolic compounds. These components are found 
in plants, and are included in human diets in the form of 
vegetables, cereals, tea, wine, and fruit juices (11). The 
main dietary groups of flavonoid include [1] flavonols [2] 
flavones [3]anthocyanidins, [4]flavanones, [5]flavanols, [6] 
Isoflavones (12). Upon ingestion, these compounds are 
metabolized to take different forms in the body (13, 14) 
indirectly protecting the neuronal population from degra-
dation, stimulating neurogenesis and augmenting 
neuronal functions (15-18). Isoflavones, one of the afore-
mentioned subtypes of flavonoids, has recently gained 
significant attention and is being studied extensively. 
Ranging from experimental studies on transgenic 
models (19, 20) to interventional trials using dietary supple-
ments rich in isoflavones, it has shown to improve cogni-
tion and memory (21-23).Isoflavones are derived from 
plants. So far soy-beans are the most abundant source 
of isoflavones whilelegumes, grains and vegetables are 
other good sources containing small amount of isofla-
vones (24, 25). Chemically, isoflavones have a non-steroidal 
structure similar to estrogens in humans and animals, 
hence they are also known as phytoestrogens. In the 
digestive tract, the primary isoflavones (genistin, daidzin, 
and glycitin) are hydrolyzed into their respective 
aglycones (genistein, daidzein, and glycitein) which are 
metabolically active, before being absorbed into the 
system (26, 27). There has been scanty literature about 
effects of Flavonoids and its subtype Isoflavones on 
cognitive improvement and neurodegenerative diseases.  
The purpose of this article is to bring together the 
evidence regarding positive effects of flavonoids, on 
cognition, and memory, particularly focusing on Isofla-
vones.
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Effect of Flavonoids on molecular pathways 
involved inAlzheimer’s disease
There are several in vitro studies showing that green tea 
extract, a source of flavonoids, could protect neurons 
from the amyloid beta-induced damages in Alzheimer’s 
disease (28, 29). Researches conducted on transgenic 
models, focused on the processes of the amyloid 
precursor protein (APP) proteolysis and amyloid beta 
metabolism in the degenerating neurons of the brain, 
which is the primary pathology in Alzheimer’s disease 
and can be possible targets in its therapy. APP can be 
processed by two pathways: 1) a nonamyloidogenic 
pathways which involve cleavage of APP to soluble APP 
by the alpha-secretase activity and 2) a formation of the 
amyloidogenic beta peptides by the beta- and gama-
secretases. Various synthetic and naturally occurring 
compounds have been analyzed for their efficacy in the 
modulation of these pathological events. Among them, 
epigallocatechingallate (EGCG) is able to regulate the 
proteolytic processing of APP both in vitro and in vivo 
(30).It has been demonstrated that flavonoids could 
promote the nonamyloidogenic alpha-secretase path-
way and reduce the formation of amyloid beta-fibrils (30) 
Flavonoids also seem to have an effect on a number of 
intracellular signaling pathways such as mitogen-
activated protein kinases (MAPKs) (31), protein kinase C 
(30), and phosphatidylinositol-3-kinase (PI-3 kinase)-Akt 
pathways (32). Oxidative stress seems to be one of the 
major stimuli for the MAPKs cascade, which might 
ultimately lead to cell survival/death. MAPKs pathways 
play a crucial role as transducers of extracellular stimuli 
into a series of intracellular phosphorylation cascades. 
These pathways exert important role in neuronal protec-
tion against a variety of insults and are essential to cell 
survival (33). In vitro studies demonstrate that EGCG could 
induce MAPKs pathways including extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), 
and p38 MAPK, which protect cells (34). For instance, in 
neuronal cell line and primary neuronal cultures, EGCG 
could prevent the decline in ERK1/2 induced by 
6-hydroxydopamine or oxidized low-density-lipoproteins 
(35,36), which are associated to attenuation of neuronal 
death and cellular injury by oxidative stress (37).
Effects of Soy Isoflavones on transgenic models 
with Alzheimer’s Disease
Focusing specifically on Soy Isoflavonoids, It has been 
reported that the hydrolyzed forms of soybeans and 
isoflavones, including glycitein (Gly) and genistein (Gen), 
have a role in inhibiting Amyloid beta-induced apoptosis 
in cultured cell (38). Mechanisms outlined by various 
studies include the protective effects of isoflavone-
induced arginase1 activity (39), inhibition of caspase 
activation and their anti-oxidant properties which shield 
against the oxidative stress on the neurons (38). Interfer-
ences in these pathways in turn reduce apoptosis of 
neurons and glial cells and promote axonal regeneration. 
Experimental studies conducted in-vitro, demonstrated 
the direct influence of isoflavonoids on proteins involved 
in the pathology of Alzheimer’s disease. Amyloid beta 
solutions were prepared, which were then fibrillized. 
When incubated with Gly and Gen, the experiment 
successfully demonstrated their anti-fibrillization effects. 
Gly and Gen were shown to directly interact with the 
fibrils and inhibited the fibrillization in a dose-dependent 
manner (40). Prior works on isoflavones have also shown 
that Gly, Gen and Daidzein (Dai), another form of hydro-
lyzed isoflavone to bind the monomeric form of 
transthyretin protein (TTR) (41) which is a protein that 
binds to the amyloid-beta preventing them to accumu-
late into plaques (42). However the mechanisms through 
which isoflavones inhibit protein fibrillation are yet to be 
analyzed. Apart from anti-fibrillization effects, Isofla-
vones were reported to play a role against cell injuries 
caused by amyloid beta. In recent studies conducted on 
transgenic models, isoflavones were indicated to reduce 
the oxidative injury induced by amyloid beta (43). It was 
also reported that Isoflavones can rescue neurons from 
amyloid beta induced cell death by interfering with the 
p38 MAP kinase pathway (44). Mixed soy isoflavones 
were shown toimprove parameters related to aging and 
Alzheimer's disease in C57BL/6J mice treated with 
d-galactose (19). In another study, it was demonstrated 
that due to isoflavone’s ability to generate PPAR-γ 
expression, it can have inhibitory effects against the 
inflammation associated with amyloid beta in cultured 
neuronal cells (45). Hence, the anti-amyloidogenic effects 
of soy isoflavones may be beneficial in dementia and AD 
and if supplemented at an earlier age, may be helpful in 
inhibiting or limiting the disease process. Isoflavones 
also possess the ability to bind to estrogen receptors. 
Gen and Dai bind with a greater affinity to the estrogen 
receptor-beta (46). This can be linked to the fact that in 
the brain, there is a high concentration of estrogen 
receptor-beta in the hippocampus (47,48), which might 
explain one of the mechanisms through which soy isofla-
vones benefit episodic memory. 
OBSERVATIONAL AND CLINICAL TRIALS
Humans are predisposed to neurodegenerative diseases 
as they age beyond 70 years(49). Recent nutritional 
studies conducted on populations indicate that 
increased intake of fruits and vegetables are associated 
with improved cognition and reduced risk of senile debili-
tating brain diseases(50, 51, 52). Blue-berry derived flavo-
noids were shown to indirectly interact with certain brain 
areas such as the hippocampus and dentate gyrus and 
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hence were associated with improvement in spatial 
memory (53, 54). In a cross-sectional study conducted over 
8335 subjects concluded that intake of isoflavones were 
inversely associated with plasma levels of C-reactive 
protein as well as other inflammatory markers in the 
blood, suggesting the anti-inflammatory role of isofla-
vones (55). An observational study in a general Japanese 
population, investigated seven different dietary patterns 
and their potential association with the risk of dementia. 
Soybean and soybean-based products were one of the 
dietary patterns observed. The results revealed that a 
higher adherence to a diet containing high proportions of 
soybean and soybean products were associated with 
reduced risk of dementia in the studied population (56). 
Most interventional clinical trials including Isoflavones 
were conducted on post-menopausal women.In a study, 
176 post-menopausal women were supplemented with 
80 mg of Isoflavones per day, followed for 6 months, 
revealed no significant association with better perfor-
mance on neuropsychological tests (57). Anotherstudy 
involved 36 post-menopausal females, were given 60mg 
of Isoflavones regularly in a span of 12 weeks, showed 
significant improvement in memory and sustained atten-
tion tasks (58), similarly in a clinical trial, 25g of soy 
protein in powder or bar form containing 154 mg of total 
Isoflavones were administered in a population of 313 
healthy post-menopausal women, for a period of 2.5 
years, the results deduced that there was a significant 
improvement in visual episodic memory after the inter-
vention (59). Better mood was also observed in 78 
healthy post-menopausal females after they received 
treatment with 60mg Isoflavones for 6 months(60). In 
another study 78 elderly individuals with mild cognitive 
deficits were given 300mg per day of soy for 6 months, 
and the results concluded that treatment with soy 
supplementation caused an significant improvement in 
memory function of the elderly as compared to the 
placebo group(61). Short-term studies conducted over 
young healthy volunteers also presented positive results. 
In a study, 16 young healthy females and 7 young 
healthy males were asked to consume 900g of 
soybeans for a period of 1 week. Mental Rotation and 
Spatial Visualization psychological tests were conducted 
over the volunteers during the days of the sampling. The 
results reported that there was a significant improve-
ment in the Mental Rotation and Spatial Visualization 
psychological tests post-treatment(21,22). Overall, clinical 
trials suggest that soy Isoflavones supplementation may 
benefit portions of memory and cognition, but less 
effects on global cognition. It may also prevent the 
decline in verbal memory observed with aging. More 
long-term clinical trials are needed on larger populations 
to detect the role of soy Isoflavones on patients 
diagnosed with Alzheimer’s disease. Skewing the dietary 
patterns towards higher proportions of soy Isoflavones 
may be beneficial for the population at high risk for 
developing Alzheimer’s disease.
CONCLUSION
In conclusion, soy Isoflavones may have a protective role 
against Alzheimer’s disease. Experimental studies on 
transgenic models have shown positive effects of soy 
Isoflavones on the biological mechanisms involved in the 
pathology of Alzheimer’s disease. Since most of the 
studies are conducted on transgenic models with scanty 
observational and clinical trials conducted over small 
sample sizes, it cannot be concluded that Isoflavones 
may prevent AD in high risk population. More research is 
needed in this area for a clinical census on the benefits 
of soy-derived Isoflavones.
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